ArticlePloS one2013

A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.

Bethany Powell Gray et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.